The Manufacturers Life Insurance Company Lowers Stock Position in Stryker Corporation $SYK

The Manufacturers Life Insurance Company decreased its stake in Stryker Corporation (NYSE:SYK) by 46.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 794,211 shares of the medical technology company’s stock after selling 696,517 shares during the period. The Manufacturers Life Insurance Company’s holdings in Stryker were worth $260,967,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in SYK. Varma Mutual Pension Insurance Co boosted its holdings in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares in the last quarter. Wealthcare Advisory Partners LLC raised its holdings in shares of Stryker by 265.2% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after buying an additional 6,774 shares in the last quarter. QRG Capital Management Inc. lifted its position in Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares during the last quarter. Fulton Breakefield Broenniman LLC lifted its position in Stryker by 41.3% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 50,123 shares of the medical technology company’s stock worth $17,617,000 after buying an additional 14,641 shares during the last quarter. Finally, Swedbank AB boosted its stake in Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after buying an additional 7,934 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK stock opened at $337.31 on Tuesday. The company has a market capitalization of $129.31 billion, a P/E ratio of 39.04, a PEG ratio of 2.12 and a beta of 0.77. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.14. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a 50 day moving average price of $315.18 and a two-hundred day moving average price of $335.37.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analysts Set New Price Targets

A number of research analysts have commented on SYK shares. BTIG Research set a $371.00 price target on shares of Stryker in a research report on Monday, July 13th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. BMO Capital Markets began coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price on the stock. Finally, Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.